Treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Lower respiratory tract infections, sinusitis and otitis media caused by β-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis.
Skin and skin structure infections caused by β-lactamase-producing strains of Staphylococcus aureus and Escherichia coli and Klebsiella spp.
Urinary tract infections caused by β-lactamase-producing strains of Escherichia coli, Klebsiella spp and Enterobacter spp.
While co-amoxiclav is indicated only for the previously mentioned conditions, infections caused by ampicillin-susceptible organisms are also amenable to treatment with co-amoxiclav due to its amoxicillin content; therefore, mixed infections caused by ampicillin-susceptible organisms and β-lactamase-producing organisms susceptible to co-amoxiclav should not require the addition of another antibiotic. Because amoxicillin has greater in vitro against Streptococcus pneumoniae than does ampicillin or penicillin, the majority of S. pneumoniae strains with intermediate susceptibility to ampicillin or penicillin are fully susceptible to amoxicillin and co-amoxiclav.
To reduce the development of drug resistant bacteria and maintain the effectiveness of amoxicillin and co-amoxiclav should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Bacteriological studies to determine the causative organisms and their susceptibility to co-amoxiclav should be performed together with any indicated surgical procedures.